Blood Cancer Clinical Trial
Official title:
The Leukemia and Lymphoma Society (LLS) National Research Registry
The Leukemia and Lymphoma Society (LLS) has built a National Research Registry to evaluate real world experiences and medical outcomes for people with blood cancer, before, during, and after blood cancer treatments.
The LLS National Research Registry is a real-world experiences and outcomes research registry; a collection of patient information and medical data, over time, about people who have a particular disease or condition, or who receive a particular treatment. The LLS National Research Registry Protocol will: 1. Answer research questions using data collected from people with blood cancers. Such research involves analyses of subject profile information completed by subjects and medical records data. 2. Obtain permission from LLS National Research Registry research subjects to have Ciitizen, a third-party engaged by LLS, act as their proxy to retrieve full medical record data including images at no cost to research subjects. Note: Patient can choose to upload their medical records into their account, directly. 3. Obtain permission from LLS National Research Registry research subjects to share summary data with research partners (like academic researchers, advocacy groups, and pharmaceutical companies) that are advancing treatments for blood cancer. "Summary data" represents the important elements of medical record data, coded for research use, with personal identifiers like name, address, and phone number removed. 4. Obtain permission from LLS National Research Registry research subjects to be contacted from time to time, for them to provide updated medical information. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
| Completed |
NCT03654404 -
A Proof-of-Concept Trial of a Positive Psychology Intervention for Allogeneic Stem Cell Transplant Patients
|
N/A | |
| Recruiting |
NCT06116032 -
Immune Profiling for Cancer Immunotherapy Response
|
||
| Recruiting |
NCT04955938 -
A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms
|
Phase 1 | |
| Recruiting |
NCT06119685 -
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05391490 -
Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor CAT19 for the Treatment of Advanced CD19+ Malignancies
|
Phase 1 | |
| Recruiting |
NCT05709522 -
Neurocognitive and Psychosocial Outcomes Among Pediatric Brain Tumor and Blood Cancer Patients
|
||
| Completed |
NCT00186225 -
Stem Cell Transplant From Matched Unrelated or Partially Matched Related Donors
|
N/A | |
| Active, not recruiting |
NCT05147311 -
Positive Psychology Intervention In HSCT
|
N/A | |
| Recruiting |
NCT04372524 -
Biomarker Verification in Pediatric Chronic GvHD: ABLE 2.0 / PTCTC GVH 1901 Study
|
||
| Completed |
NCT01957579 -
A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies
|
Phase 1 | |
| Completed |
NCT00185640 -
Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies
|
Phase 2 | |
| Withdrawn |
NCT04390542 -
Intervention for Caregivers of Patients Undergoing HSCT or CAR T-cell Therapy
|
N/A | |
| Completed |
NCT04419623 -
A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer
|
Phase 1 | |
| Recruiting |
NCT05873205 -
Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation
|
Phase 2 | |
| Completed |
NCT00962494 -
Cancer: Thriving and Surviving Online Workshop and Study for Cancer Survivors
|
Phase 2 | |
| Completed |
NCT00185796 -
TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD
|
Phase 2 | |
| Completed |
NCT04236063 -
Rehabilitation Needs of the Malaysian Haematological Cancer Survivors
|
||
| Recruiting |
NCT05692713 -
Polyomic Biomarker Verification in Adult Chronic Graft-Versus-Host Disease (ABLE3.0/CTTC2201)
|
||
| Recruiting |
NCT06250595 -
European Rare Blood Disorders Platform (ENROL)
|